Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial.

Ghader Mohammadnezhad Farhad Assarzadegan Mohsen Koosha Hadi Esmaily

Published in: Headache (2024)

This study's findings support the potential of a daily 2000 mg EPA as a prophylactic pharmacotherapy in chronic migraine management, specifically in mitigating migraine attacks, migraine headache days, and overall quality of life.

Keyphrases

stem cells
risk assessment
smoking cessation
bone marrow
double blind
human health